Image Metrix chosen as CRO for Image Management in AMI Bone Imaging Trial
ACR Image Metrix chosen as CRO for Image Management in Groundbreaking AMI Bone Imaging Trial
(January 27, 2009; Philadelphia, PA)-An innovative clinical trial designed to compare two bone-imaging techniques will utilize more than 300 patients at 11 different sites in the U.S.
ACR Image Metrix has been selected by the Academy of Molecular Imaging (AMI) to be the contract research organization (CRO) providing database/data management and image handling resources for a groundbreaking trial comparing 18F-Sodium Fluoride PET/CT imaging with conventional 99mTc-MDP bone-imaging techniques to localize carcinogenic bone metastasis.
“Our unique connection with the American College of Radiology (ACR) has shown to give us tremendous creditability from the start,” said Michael J. Morales, ACR Image Metrix general manager. “It positions us as having both the scientific and operational horsepower to compete at a very high level in the CRO marketplace.”
“Recent trials at ACR Image Metrix have focused on the capacity of molecular and functional imaging to serve as biomarkers in determining the effectiveness of anticancer treatments,” Morales said. “We were a natural partner for AMI.”
AMI has secured funding from the Institute for Molecular Technologies (IMT), as well as broad academic collaboration. Among participating institutions are Duke, Stanford and Dartmouth Universities, Memorial Sloan-Kettering, MD Anderson and Cedars-Sinai Medical Center.
About ACR Image Metrix
ACR Image Metrix, located in the American College of Radiology Clinical Research Center, applies imaging techniques as a predictive and prognostic biomarker improving the efficiency for drug development programs. The world-class team of physicians and scientists at ACR Image Metrix work with pharmaceutical, biotech and medical device companies to increase the efficiency of drug and device development programs by integrating the appropriate imaging modalities. ACR Image Metrix has years of experience and proven expertise in employing state-of-the-art technologies provide a complete line of imaging services.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
